Ramesh Konanki
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Ramesh Konanki has a total of 85 co-authors. Here are the top co-authors by number of shared publications:
Lokesh Lingappa
Department of Neurology, Rainbow Children's Hospital, Hyderabad, India
5 shared publicationsDandu Ravi Varma
Citi Neuro Center Hospital Hyderabad India
3 shared publicationsNihaal Reddy
Department of Radiodiagnosis, Rainbow Children’s Hospital, Hyderabad, Telangana, India
3 shared publications- Lokesh Lingappa
Department of Pediatric Neurology, Rainbow Children’s Hospital, Hyderabad, India
2 shared publications Maya Thomas
Department of Neurological Sciences, Paediatric Neurology Unit, Christian Medical College, Vellore, Tamil Nadu, India
2 shared publications- Prasanthi Aripirala
Department of Pediatric Neurology Rainbow Children's Hospital and Perinatal Center Hyderabad India
2 shared publications
Latest Publications
- Open Access
- 30 October 2026
- Published by Wolters Kluwer Health in Neurology India
- Vol. 74 (6) , 1051-1057
Clinical and Neuroimaging Findings in Children with Pathogenic Variants in PCDH12 Gene: Report of Four Cases from South India
Introduction: Protocadherins (PCDHs) are a family of cell-surface proteins that belong to the cadherin superfamily. PCDH12 is widely expressed in human tissues, including the lung, placenta, spleen, and brain. Loss-of-function variants in the protocadherin12 ( PCDH12) gene have been implicated in an autosomal recessive disorder characterized by microcephaly, seizures, spasticity, and brain calcifications. Here, we describe the clinical, neuroimaging, and genotypic findings in four unrelated children with pathogenic or likely pathogenic biallelic variants in the PCDH12 gene. Case Summary: Our patients had global developmental delay, dysmorphic features, microcephaly, axial hypotonia, spasticity, dystonia, and ataxia. Three of our patients exhibited early-onset seizures from infancy with variable semiology. Neuroimaging in our patients revealed diencephalic-mesencephalic junction dysplasia (DMJD), enlargement of the lateral ventricles, hypoplasia of the corpus callosum, butterfly sign in the midbrain, and dysmorphic basal ganglia. Brain calcification was not observed in our patients. The constellation of clinical and imaging findings in PCDH12 -related DMJD may be attributable to alterations in the formation and maintenance of neural circuits. Our patients 1 and 2 harbored novel frameshift variants in the PCDH12 gene, and patient 4 harbored novel nonsense variants in the PCDH12 gene, while patient 3 had previously reported nonsense variants resulting in a truncated protein that might have resulted in severe functional defects. Conclusion: This case series expands the phenotypic, neuroimaging, and genotypic spectrum in patients with biallelic variants in the PCDH12 gene.
- 30 October 2026
- Published by Wolters Kluwer Health in Neurology India
- Vol. 74 (6) , 1051-1057
Open AccessClinical and Neuroimaging Findings in Children with Pathogenic Variants in PCDH12 Gene: Report of Four Cases from South India
Introduction: Protocadherins (PCDHs) are a family of cell-surface proteins that belong to the cadherin superfamily. PCDH12 is widely expressed in human tissues, including the lung, placenta, spleen, and brain. Loss-of-function variants in the protocadherin12 ( PCDH12) gene have been implicated in an autosomal recessive disorder characterized by microcephaly, seizures, spasticity, and brain calcifications. Here, we describe the clinical, neuroimaging, and genotypic findings in four unrelated children with pathogenic or likely pathogenic biallelic variants in the PCDH12 gene. Case Summary: Our patients had global developmental delay, dysmorphic features, microcephaly, axial hypotonia, spasticity, dystonia, and ataxia. Three of our patients exhibited early-onset seizures from infancy with variable semiology. Neuroimaging in our patients revealed diencephalic-mesencephalic junction dysplasia (DMJD), enlargement of the lateral ventricles, hypoplasia of the corpus callosum, butterfly sign in the midbrain, and dysmorphic basal ganglia. Brain calcification was not observed in our patients. The constellation of clinical and imaging findings in PCDH12 -related DMJD may be attributable to alterations in the formation and maintenance of neural circuits. Our patients 1 and 2 harbored novel frameshift variants in the PCDH12 gene, and patient 4 harbored novel nonsense variants in the PCDH12 gene, while patient 3 had previously reported nonsense variants resulting in a truncated protein that might have resulted in severe functional defects. Conclusion: This case series expands the phenotypic, neuroimaging, and genotypic spectrum in patients with biallelic variants in the PCDH12 gene.
- Open Access
- 13 February 2026
- Published by Springer Nature in Indian Pediatrics
- Vol. 63 (3) , 151-152
Guillain-Barré Syndrome: Changing Landscape and Environmental Influences
- 13 February 2026
- Published by Springer Nature in Indian Pediatrics
- Vol. 63 (3) , 151-152
Open AccessGuillain-Barré Syndrome: Changing Landscape and Environmental Influences
- 21 January 2025
- Published by Elsevier in Pediatric Neurology
- Vol. 165, 9-15
Challenges in Management of Febrile Infection-Related Epilepsy Syndrome: Real-World Experience From a Large Cohort of Pediatric Patients
- 21 January 2025
- Published by Elsevier in Pediatric Neurology
- Vol. 165, 9-15
Challenges in Management of Febrile Infection-Related Epilepsy Syndrome: Real-World Experience From a Large Cohort of Pediatric Patients
KCTD7‐related progressive myoclonic epilepsy: Report of 42 cases and review of literature
Objective: KCTD7‐related progressive myoclonic epilepsy (PME) is a rare autosomal‐recessive disorder. This study aimed to describe the clinical details and genetic variants in a large international cohort.Methods: Families with molecularly confirmed diagnoses of KCTD7‐related PME were identified through international collaboration. Furthermore, a systematic review was done to identify previously reported cases. Salient demographic, epilepsy, treatment, genetic testing, electroencephalographic (EEG), and imaging‐related variables were collected and summarized.Results: Forty‐two patients (36 families) were included. The median age at first seizure was 14 months (interquartile range = 11.75–22.5). Myoclonic seizures were frequently the first seizure type noted (n = 18, 43.9%). EEG and brain magnetic resonance imaging findings were variable. Many patients exhibited delayed development with subsequent progressive regression (n = 16, 38.1%). Twenty‐one cases with genetic testing available (55%) had previously reported variants in KCTD7, and 17 cases (45%) had novel variants in KCTD7 gene. Six patients died in the cohort (age range = 1.5–21 years). The systematic review identified 23 eligible studies and further identified 59 previously reported cases of KCTD7‐related disorders from the literature. The phenotype for the majority of the reported cases was consistent with a PME (n = 52, 88%). Other reported phenotypes in the literature included opsoclonus myoclonus ataxia syndrome (n = 2), myoclonus dystonia (n = 2), and neuronal ceroid lipofuscinosis (n = 3). Eight published cases died over time (14%, age range = 3–18 years).Significance: This study cohort and systematic review consolidated the phenotypic spectrum and natural history of KCTD7‐related disorders. Early onset drug‐resistant epilepsy, relentless neuroregression, and severe neurological sequalae were common. Better understanding of the natural history may help future clinical trials.
KCTD7‐related progressive myoclonic epilepsy: Report of 42 cases and review of literature
Objective: KCTD7‐related progressive myoclonic epilepsy (PME) is a rare autosomal‐recessive disorder. This study aimed to describe the clinical details and genetic variants in a large international cohort.Methods: Families with molecularly confirmed diagnoses of KCTD7‐related PME were identified through international collaboration. Furthermore, a systematic review was done to identify previously reported cases. Salient demographic, epilepsy, treatment, genetic testing, electroencephalographic (EEG), and imaging‐related variables were collected and summarized.Results: Forty‐two patients (36 families) were included. The median age at first seizure was 14 months (interquartile range = 11.75–22.5). Myoclonic seizures were frequently the first seizure type noted (n = 18, 43.9%). EEG and brain magnetic resonance imaging findings were variable. Many patients exhibited delayed development with subsequent progressive regression (n = 16, 38.1%). Twenty‐one cases with genetic testing available (55%) had previously reported variants in KCTD7, and 17 cases (45%) had novel variants in KCTD7 gene. Six patients died in the cohort (age range = 1.5–21 years). The systematic review identified 23 eligible studies and further identified 59 previously reported cases of KCTD7‐related disorders from the literature. The phenotype for the majority of the reported cases was consistent with a PME (n = 52, 88%). Other reported phenotypes in the literature included opsoclonus myoclonus ataxia syndrome (n = 2), myoclonus dystonia (n = 2), and neuronal ceroid lipofuscinosis (n = 3). Eight published cases died over time (14%, age range = 3–18 years).Significance: This study cohort and systematic review consolidated the phenotypic spectrum and natural history of KCTD7‐related disorders. Early onset drug‐resistant epilepsy, relentless neuroregression, and severe neurological sequalae were common. Better understanding of the natural history may help future clinical trials.
- 12 December 2023
- Published by Elsevier in Journal of Clinical Orthopaedics and Trauma
- Vol. 47, 102316
Impact of COVID lockdown: Increased prevalence of symptomatic Vitamin D deficiency in adolescents
- 12 December 2023
- Published by Elsevier in Journal of Clinical Orthopaedics and Trauma
- Vol. 47, 102316
Impact of COVID lockdown: Increased prevalence of symptomatic Vitamin D deficiency in adolescents
- 15 November 2022
- Published by Wiley in Developmental Medicine & Child Neurology
- Vol. 65 (6) , 847-854
Cryptogenic posterior circulation stroke in children
We aimed to evaluate the percentage of posterior circulation arterial ischaemic stroke (PCAIS) caused by craniovertebral junction (CVJ) anomalies and describe their clinical course. Children admitted to a tertiary care paediatric hospital with PCAIS between July 2017 and December 2020 were assessed retrospectively for disease aetiology. We reviewed the clinical, radiological, and surgical details of children with evidence of CVJ anomalies. Fourteen (24.1%) of 58 children admitted with arterial ischaemic stroke had posterior circulation involvement. The mean age of patients presenting with posterior circulation stroke was 6 years 6 months (range 3 months-15 years), 11 were male. Six of 14 cases with PCAIS were due to CVJ anomaly, their ages ranged from 4 months to 15 years (two age ranges were noted, 4 months-4 years and 11-15 years), four were male. Two children had atlantoaxial dislocation with basilar invagination, two had Bow Hunter syndrome with Chiari malformation type 1 (one with completed stroke), one had Chiari malformation type 1 alone, and one presented with Farber disease with proatlas segmentation anomaly in CVJ. The time lag to stroke and CVJ diagnosis ranged from 2 weeks to 24 months. A dynamic angiogram was required to evaluate biomechanical changes on scans with inconclusive findings on standard stroke imaging. CVJ anomalies are an important treatable cause of paediatric posterior circulation stroke. Cervical spine x-ray in flexion and extension should be done in all patients with posterior circulation stroke beyond the acute period. In cryptogenic aetiology, provocative angiography with guarded neck rotation should be considered to evaluate possible dynamic vertebral artery compression.
- 15 November 2022
- Published by Wiley in Developmental Medicine & Child Neurology
- Vol. 65 (6) , 847-854
Cryptogenic posterior circulation stroke in children
We aimed to evaluate the percentage of posterior circulation arterial ischaemic stroke (PCAIS) caused by craniovertebral junction (CVJ) anomalies and describe their clinical course. Children admitted to a tertiary care paediatric hospital with PCAIS between July 2017 and December 2020 were assessed retrospectively for disease aetiology. We reviewed the clinical, radiological, and surgical details of children with evidence of CVJ anomalies. Fourteen (24.1%) of 58 children admitted with arterial ischaemic stroke had posterior circulation involvement. The mean age of patients presenting with posterior circulation stroke was 6 years 6 months (range 3 months-15 years), 11 were male. Six of 14 cases with PCAIS were due to CVJ anomaly, their ages ranged from 4 months to 15 years (two age ranges were noted, 4 months-4 years and 11-15 years), four were male. Two children had atlantoaxial dislocation with basilar invagination, two had Bow Hunter syndrome with Chiari malformation type 1 (one with completed stroke), one had Chiari malformation type 1 alone, and one presented with Farber disease with proatlas segmentation anomaly in CVJ. The time lag to stroke and CVJ diagnosis ranged from 2 weeks to 24 months. A dynamic angiogram was required to evaluate biomechanical changes on scans with inconclusive findings on standard stroke imaging. CVJ anomalies are an important treatable cause of paediatric posterior circulation stroke. Cervical spine x-ray in flexion and extension should be done in all patients with posterior circulation stroke beyond the acute period. In cryptogenic aetiology, provocative angiography with guarded neck rotation should be considered to evaluate possible dynamic vertebral artery compression.
- Open Access
- 22 September 2022
- Published by MDPI AG in Bioengineering
- Vol. 9 (10) , 498
Diagnostic and Therapeutic Roles of the “Omics” in Hypoxic–Ischemic Encephalopathy in Neonates
Perinatal asphyxia and neonatal encephalopathy remain major causes of neonatal mortality, despite the improved availability of diagnostic and therapeutic tools, contributing to neurological and intellectual disabilities worldwide. An approach using a combination of clinical data, neuroimaging, and biochemical parameters is the current strategy towards the improved diagnosis and prognosis of the outcome in neonatal hypoxic–ischemic encephalopathy (HIE) using bioengineering methods. Traditional biomarkers are of little use in this multifactorial and variable phenotype-presenting clinical condition. Novel systems of biology-based “omics” approaches (genomics, transcriptome proteomics, and metabolomics) may help to identify biomarkers associated with brain and other tissue injuries, predicting the disease severity in HIE. Biomarker studies using omics technologies will likely be a key feature of future neuroprotective treatment methods and will help to assess the successful treatment and long-term efficacy of the intervention. This article reviews the roles of different omics as biomarkers of HIE and outlines the existing knowledge of our current understanding of the clinical use of different omics molecules as novel neonatal brain injury biomarkers, which may lead to improved interventions related to the diagnostic and therapeutic aspects of HIE.
- 22 September 2022
- Published by MDPI AG in Bioengineering
- Vol. 9 (10) , 498
Open AccessDiagnostic and Therapeutic Roles of the “Omics” in Hypoxic–Ischemic Encephalopathy in Neonates
Perinatal asphyxia and neonatal encephalopathy remain major causes of neonatal mortality, despite the improved availability of diagnostic and therapeutic tools, contributing to neurological and intellectual disabilities worldwide. An approach using a combination of clinical data, neuroimaging, and biochemical parameters is the current strategy towards the improved diagnosis and prognosis of the outcome in neonatal hypoxic–ischemic encephalopathy (HIE) using bioengineering methods. Traditional biomarkers are of little use in this multifactorial and variable phenotype-presenting clinical condition. Novel systems of biology-based “omics” approaches (genomics, transcriptome proteomics, and metabolomics) may help to identify biomarkers associated with brain and other tissue injuries, predicting the disease severity in HIE. Biomarker studies using omics technologies will likely be a key feature of future neuroprotective treatment methods and will help to assess the successful treatment and long-term efficacy of the intervention. This article reviews the roles of different omics as biomarkers of HIE and outlines the existing knowledge of our current understanding of the clinical use of different omics molecules as novel neonatal brain injury biomarkers, which may lead to improved interventions related to the diagnostic and therapeutic aspects of HIE.
- 1 January 2022
- Published by Elsevier in European Journal of Paediatric Neurology
- Vol. 36, 93-98
Thiamine-responsive, life-threatening, pulmonary hypertensive crisis with encephalopathy in young infants: A case series
- 1 January 2022
- Published by Elsevier in European Journal of Paediatric Neurology
- Vol. 36, 93-98
Thiamine-responsive, life-threatening, pulmonary hypertensive crisis with encephalopathy in young infants: A case series
- 1 July 2021
- Published by Elsevier in European Journal of Paediatric Neurology
- Vol. 33, 86-93
The spectrum of acute leukoencephalopathy with restricted diffusion (ALERD): A case series and review of literature
- 1 July 2021
- Published by Elsevier in European Journal of Paediatric Neurology
- Vol. 33, 86-93
The spectrum of acute leukoencephalopathy with restricted diffusion (ALERD): A case series and review of literature
- 29 November 2020
- Published by Springer Nature in Indian Pediatrics
- Vol. 58 (1) , 71-76
Research Letters
- 29 November 2020
- Published by Springer Nature in Indian Pediatrics
- Vol. 58 (1) , 71-76
Research Letters